A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma. Zakharia Y, Kim D, Freesmeier M, Frees M, et al. Cancer 2026;132:e70326.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zakharia Y, Kim D, Freesmeier M, Frees M, et al. A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma. Cancer 2026;132:e70326.
PMID: 41701511